Ignite Creation Date:
2024-05-06 @ 7:45 PM
Last Modification Date:
2024-10-26 @ 3:13 PM
Study NCT ID:
NCT06120803
Status:
RECRUITING
Last Update Posted:
2024-04-01
First Post:
2023-11-01
Brief Title:
Esomeprazole and Radiation Induced Esophagitis
Sponsor:
Rush University Medical Center
Organization:
Rush University Medical Center
Study Overview
Official Title:
Effect of Esomeprazole on Radiation Induced Esophagitis in Non-small Cell Lung Cancer EERENs A Phase II Single Arm Study
Status:
RECRUITING
Status Verified Date:
2024-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
EERENs
Brief Summary:
Thoracic radiation therapy combined with chemotherapy with or without immunotherapy is the cornerstone of management in patients with locally advanced non-small cell lung cancer NSCLC
Detailed Description:
Thoracic radiation therapy combined with chemotherapy with or without immunotherapy is the cornerstone of management in patients with locally advanced non-small cell lung cancer NSCLC Despite advancement in radiation delivery techniques about 13 of patients who undergo thoracic radiation therapy TRT for advanced NSCLC suffer from symptoms of radiation-induced inflammation of the esophagus also known as radiation-induced esophagitis RE Radiation induced esophagitis can have detrimental effect on quality-of-life and can result in unplanned treatment interruptions If not treated appropriately acute severe radiation induced esophagitis might also progress to long-term consequences such as esophageal stricture Existing management of radiation induced esophagitis entails addressing the symptoms and nutritional needs Anecdotal reports have shown improvement in radiation induced esophagitis symptoms with proton pump inhibitors PPI however no robust prospective evidence exists to support use of PPI to manage radiation induced esophagitis to mitigate detrimental impact on QoL Recent studies have shown that the PPI esomeprazole has antioxidant anti-inflammatory and antifibrotic properties and it potentiates the effect of ionizing radiation on cancer cells
The investigators hypothesize that the use of esomeprazole will reduce the frequency of symptomatic grade 2 radiation induced esophagitis compared to reported rates in literature To address this hypothesis the investigators propose a phase II study with locally advanced non-small cell lung cancer NSCLC patients with the following objectives The primary objective is to evaluate the frequency of acute symptomatic RE and associated patient-reported symptoms with use of 40 mg of esomeprazole two pills of 20 mg strength of esomeprazole once daily for the duration of TRT and for two weeks after completion of TRT Finally as exploratory objectives the investigators plan to identify orthogonal biomarkers that predict radiation induced esophagitis RE in the context of using esomeprazole
The frequency of symptomatic radiation induced esophagitis at 2 weeks after RT completion and at 3 months from the start of TRT will be documented in a cohort of patients with locally advanced NSCLC receiving TRT EQD2 of 45 Gy or higher with concomitant chemotherapy and estimated esophageal maximum dose of 30 Gy or higher Both clinician-reported metrics Common Terminology Criteria for Adverse Events version 50 and patient-reported metrics Patient-Reported Outcomes version of the CTCAE PRO-CTCAE will be used
As part of exploratory objectives investigators will investigate correlative biomarkers that could predict radiation-induced esophagitis in the context of using esomeprazole
This work is significant as it will provide important evidence to support the use of esomeprazole a readily available over-the-counter medication with thoracic radiation therapy to reduce the frequency of symptomatic radiation induced esophagitis given the lack of clinical evidence in the existing literature supporting this premise
The investigators hypothesize that the use of esomeprazole will reduce the frequency of symptomatic grade 2 radiation induced esophagitis compared to reported rates in literature To address this hypothesis the investigators propose a phase II study with locally advanced non-small cell lung cancer NSCLC patients with the following objectives The primary objective is to evaluate the frequency of acute symptomatic RE and associated patient-reported symptoms with use of 40 mg of esomeprazole two pills of 20 mg strength of esomeprazole once daily for the duration of TRT and for two weeks after completion of TRT Finally as exploratory objectives the investigators plan to identify orthogonal biomarkers that predict radiation induced esophagitis RE in the context of using esomeprazole
The frequency of symptomatic radiation induced esophagitis at 2 weeks after RT completion and at 3 months from the start of TRT will be documented in a cohort of patients with locally advanced NSCLC receiving TRT EQD2 of 45 Gy or higher with concomitant chemotherapy and estimated esophageal maximum dose of 30 Gy or higher Both clinician-reported metrics Common Terminology Criteria for Adverse Events version 50 and patient-reported metrics Patient-Reported Outcomes version of the CTCAE PRO-CTCAE will be used
As part of exploratory objectives investigators will investigate correlative biomarkers that could predict radiation-induced esophagitis in the context of using esomeprazole
This work is significant as it will provide important evidence to support the use of esomeprazole a readily available over-the-counter medication with thoracic radiation therapy to reduce the frequency of symptomatic radiation induced esophagitis given the lack of clinical evidence in the existing literature supporting this premise
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?:
None